Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from MicroPort CardioFlow Medtech Corp. ( (HK:2160) ).
MicroPort CardioFlow Medtech Corp. announced its annual results for 2024, showing a 7.5% increase in revenue to RMB361.6 million, driven by the global commercialization of its TAVI products and the launch of new LAAC systems in China. Despite facing a loss of RMB53.3 million, the company significantly reduced its losses compared to the previous year, thanks to effective cost management and operational efficiency improvements. The structural heart diseases industry in China continues to grow steadily, supported by policy, market demand, and medical insurance access, although it faces challenges from economic conditions and competition.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corp. is a company in the medical technology industry, focusing on the development and commercialization of products for the treatment of structural heart diseases. Its primary products include transcatheter aortic valve implantation (TAVI) devices and left atrial appendage closure (LAAC) systems, with a market focus on both domestic and international markets.
YTD Price Performance: 66.18%
Average Trading Volume: 3,654,845
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.65B
See more data about 2160 stock on TipRanks’ Stock Analysis page.